Year-end Sale % OFF 
Abstract
We investigated whether the Neurofibromatosis type-1(NF1) gene was of prognostic relevance to gastric cancer (GC) patients. Immunohistochemical staining of 160 matched GC tumor and adjacent normal tissue samples showed that 58.1% (93/160) of GC samples were NF1-positive as compared to 94.4% (151/160) of normal tissue samples (χ2=58.05, P <0.001). qRT-PCR analysis revealed that NF1 mRNA expression is lower in GC tissues than normal tissues (χ2=34.23, P <0.001). Moreover, NF1 protein and mRNA levels were associated with T stage (P <0.05) and TNM (P <0.001). No association was observed with other clinicopathological parameters, including gender, age, tumor size, lymph-node metastasis, cancer differentiation and distant metastasis (all P >0.05). Kaplan-Meier analysis revealed that negative or low NF1 were associated with poor overall survival (OS) in gastric cancer patients (P<0.001). Further univariate and multivariate cox regression analysis also showed that NF1 expression was an independent risk factor of survival of GC patients. These data show that NF1 has prognostic relevance to clinical outcomes in gastric cancer patients.
Highlights
Gastric cancer (GC) is the third leading cause of cancer-related deaths and the fourth most common malignant tumors [1]
We investigated whether the Neurofibromatosis type-1(NF1) gene was of prognostic relevance to gastric cancer (GC) patients
Immunohistochemical staining of 160 matched GC tumor and adjacent normal tissue samples showed that 58.1% (93/160) of GC samples were NF1-positive as compared to 94.4% (151/160) of normal tissue samples (χ2=58.05, P
Summary
Gastric cancer (GC) is the third leading cause of cancer-related deaths and the fourth most common malignant tumors [1]. New prognostic tumor markers and therapeutic targets are necessary to improve the clinical outcomes for GC patients. Neurofibromatosis type-1(NF1) or von Recklinghausen disease is a common autosomal dominant condition affecting the nervous system with an estimated incidence of about 1 in 3,000-4,000 individuals worldwide [5, 6]. It is a multi-system disease associated with many cancers [7, 8]. Vizcaino et al demonstrated that glioma patients with low NF1 expression were associated with poor overall survival and diseasespecific survival [17]. We analyzed the prognostic relevance of NF1 for GC patients
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
